Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy-March 2024-www.financetom.com

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

Sep 2, 2025 5:08 AM

Sept 2 (Reuters) - Arrowhead Pharmaceuticals ( ARWR )

said on Tuesday it will receive up to $2 billion from Novartis

for an exclusive worldwide license to its experimental

therapy that targets neuromuscular conditions such as

Parkinson's Disease.

Previous page： OnePlus 7 Pro: Best Android value flagship smartphone Next page： Twitter suspends accounts of many China activists

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

OnePlus 7 Pro: Best Android value flagship smartphone

Jun 2, 2019

OnePlus, along with Samsung and Apple, accounted for 90 percent of the premium segment shipments in Q1 2019.

Twitter suspends accounts of many China activists

Jun 2, 2019

Twitter suspended a large number of accounts, including those belonging to Chinese political commentators.

'Nokia 6.2' set for India launch on Thursday

Jun 1, 2019

The Nokia 6.2 is rumoured to be the global variant of the Nokia X71 that was launched in Taiwan a few weeks ago.

PUBG: Uninstall the game before it kills 'em young

Jun 2, 2019

With smartphones getting cheaper and better, mobile gaming has taken off and millions of Indian youth are now hooked to games like PlayerUnknown Battleground (PUBG).